Between September 2006 and July 2013, 31 patients were treated with AZA for relapse of their myeloid malignancy following allo-HSCT. As per institutional guidelines, patients received AZA after ...

Although all three mutants differentially predispose to myeloid malignancies, there was no difference in leukemia-free survival for GATA2 patients. Despite intense interest, the molecular ...

1. Visser O, Trama A, Maynadie M, et al.: Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012; 48: 3257–66 CrossRef MEDLINE 2. Wolff D, Bertz H, Greinix H ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

for test results in myeloid malignancies. The test also provides comprehensive genomic profiling for cancers such as lung, colon, breast, and melanoma. The Myeloid genomics test analyzes 79 genes ...

Leukemia, lymphoma, and myeloma will account for an estimated 10% of new cancer cases this year in the U.S. These malignancies defy ... Hodgkin lymphoma to acute myeloid leukemia, for which ...

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.